Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa

Abstract

<jats:title>Abstract</jats:title> <jats:p>The natural pattern of progression of Parkinson’s disease is largely unknown because patients are conventionally followed on treatment. As Parkinson’s disease progresses, the true magnitude of the long-duration response to levodopa remains unknown, because it can only be estimated indirectly in treated patients. We aimed to describe the natural course of motor symptoms by assessing the natural OFF in consecutive Parkinson’s disease patients never exposed to treatment (drug-naïve), and to investigate the effects of daily levodopa on the progression of motor disability in the OFF medication state over a 2-year period. In this prospective naturalistic study in sub-Saharan Africa, 30 Parkinson’s disease patients (age at onset 58 ± 14 years, disease duration 7 ± 4 years) began levodopa monotherapy and were prospectively assessed using the Unified Parkinson’s disease Rating Scale (UPDRS). Data were collected at baseline, at 1-year and 2-years follow-up. First-ever levodopa intake induced a significant improvement in motor symptoms (natural OFF versus ON state UPDRS-III 41.9 ± 15.9 versus 26.8 ± 15.1, respectively; P &amp;lt; 0.001). At 1-year follow-up, OFF state UPDRS-III score after overnight withdrawal of levodopa was considerably lower than natural OFF (26.5 ± 14.9; P &amp;lt; 0 .001). This effect was not modified by disease duration. At the 2-year follow-up, motor signs after overnight OFF (30.2 ± 14.2) were still 30% milder than natural OFF (P = 0.001). The ON state UPDRS-III at the first-ever levodopa challenge was similar to the overnight OFF score at 1-year follow-up and the two conditions were correlated (r = 0.72, P &amp;lt; 0.001). Compared to the natural progression of motor disability, levodopa treatment resulted in a 31% lower annual decline in UPDRS-III scores in the OFF state (3.33 versus 2.30 points/year) with a lower model’s variance explained by disease duration (67% versus 36%). Using the equation regressed on pretreatment data, we predicted the natural OFF at 1-year and 2-year follow-up visits and estimated that the magnitude of the long-duration response to levodopa ranged between 60% and 65% of total motor benefit provided by levodopa, independently of disease duration (P = 0.13). Although levodopa therapy was associated with motor fluctuations, overnight OFF disability during levodopa was invariably less severe than the natural course of the disease, independently of disease duration. The same applies to the yearly decline in UPDRS-III scores in the OFF state. Further research is needed to clarify the mechanisms underlying the long-duration response to levodopa in Parkinson’s disease. Understanding the natural course of Parkinson’s disease and the long-duration response to levodopa may help to develop therapeutic strategies increasing its magnitude to improve patient quality of life and to better interpret the outcome of randomized clinical trials on disease-modifying therapies that still rely on the overnight OFF to define Parkinson’s disease progression.</jats:p>

Trojan Horse Delivery of 4,4′‐Dimethoxychalcone for Parkinsonian Neuroprotection

“…DA neuron replenishment represents a cardinal target for both idiopathic and symptomatic PD therapeutics; however, as the disease progresses, long‐term therapy may induce dyskinesia and other motor complications. [ 6 ] Although several reprogrammable and gene‐editing approaches have yielded promising benefits for alleviating neurological deficits and DA neuron loss in PD animal models, investigations are still preclinical, and technical challenges and ethical considerations must be overcome before their clinical application. [ 7 ]…”

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease

“…Notably, motor factor scores did not correlate with each other, and this independence amongst scores challenges the use of summated MDS-UPDRS III ratings as a primary clinical outcome measure, as motor factor scores may provide distinct clinical information about therapeutic response. While our PD cohort was of comparable size to previous MEG studies ( Heinrichs-Graham et al, 2014 ; Cao et al, 2020 ; Vinding et al, 2020 ), future studies that leverage the factor score methodology in larger cohorts will be crucial to expand the needed quantitative information of therapeutic response in SDR, long-duration L-Dopa response ( Anderson and Nutt, 2011 ; Cilia et al, 2020 ), and other interventional therapies.…”

“…Subjects 2, 5, and 9 were not included in SVM analysis due to prominent muscle, tremor, or imaging artifacts, respectively. larger cohorts will be crucial to expand the needed quantitative information of therapeutic response in SDR, long-duration L-Dopa response (Anderson and Nutt, 2011;Cilia et al, 2020), and other interventional therapies. Linear SVM identified the frequency bands that best distinguished LEVODOPA-OFF from LEVODOPA-ON, and frequency band weights revealed substantial inter-subject variability in MEG changes during SDR.…”

Nanomaterial‐Based Electrochemical Sensors: Mechanism, Preparation, and Application in Biomedicine

“…[ 91 ] Drug monitoring benefits the personalized assessment of prognosis results for pharmacokinetic study and therapeutic evaluation. [ 92 ] Tai et al presented a wearable band with nanodendritic materials, to continuously monitor caffeine from human sweats (Figure 5C). [ 93 ] In 2018, they further extended the targeted drug to Levodopa, i.e., a treatment for Parkinson's disease.…”